Great results from Syngene.
http://corporates.bseindia.com/xml-data/corpfiling/AttachLive/196A4865_E4EE_4EAD_9BF6_259895AF394F_191354.pdf
Revenues up 28% (compared to Q2FY16)
PAT up 31%
EBITDA margins at 33%
“Our recent capacity expansion in manufacturing services has helped us keep pace with increasing requirements of our clients.”
“Growth was specially strong in development and manufacturing services. We had added capacities in the development and manufacturing vertical over the past 2 fiscals, which helped fuel this growth”
“We continue to plan investments towards capacity additions and capability enhancements in both discovery and development space. Key ongoing investments in these areas include a new research center, a formulations center and a large molecules manufacturing unit at our current site. In terms of new capabilities, we are currently investing in a viral testing facility and an oligonucleotide pilot plant.”
| Subscribe To Our Free Newsletter |
